Giotrif 20 mg film-coated tablets
Spain
Table of Contents
Package leaflet: Information for the user
Introduction
Package leaflet: Information for the patient
GIOTRIF 20mg film-coated tablets
afatinib
Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.
- Keep this leaflet, as you may need to read it again.
- If you have any questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
- If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.
Contents of the leaflet
- What GIOTRIF is and what it is used for
- What you need to know before taking GIOTRIF
- How to take GIOTRIF
- Possible side effects
- How to store GIOTRIF
- Contents of the pack and other information
1. What GIOTRIF is and what it is used for
GIOTRIF is a medicine that contains the active substance afatinib. It works by blocking the activity of a group of proteins called the ErbB family (including EGFR [Epidermal Growth Factor Receptor or ErbB1], HER2 [ErbB2], ErbB3, and ErbB4]. These proteins are involved in the growth and spread of cancer cells and may be affected by changes (mutations) in the genes that produce them. By blocking the activity of these proteins, this medicine can inhibit the growth and spread of cancer cells.
This medicine is used alone to treat adult patients with a specific type of lung cancer (non-small cell lung cancer):
- characterized by a change (mutation) in the EGFR gene. Your doctor may prescribe GIOTRIF as your first treatment or if previous chemotherapy has been insufficient.
- squamous type if previous treatment with chemotherapy has been insufficient.
2. What you need to know before starting to take GIOTRIF
Do not take GIOTRIF
- if you are allergic to afatinib or to any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine:
- if you are a woman, weigh less than 50 kg, or have kidney problems. If any of these apply to you, your doctor may monitor you more closely, as side effects may be more severe.
- if you have a history of lung inflammation (interstitial lung disease).
- if you have liver problems. Your doctor may perform liver function tests. Treatment with this medicine is not recommended if you have severe liver disease.
- if you have a history of eye disorders such as severe dry eye, inflammation of the clear layer at the front of the eye (cornea), or corneal ulcers, or if you wear contact lenses.
- if you have a history of heart problems. Your doctor may monitor you more closely.
Tell your doctor immediately while taking this medicine:
- if you have diarrhea. It is important to start treatment at the first signs of diarrhea.
- if you develop a skin rash. It is important to start treatment for the rash as soon as possible.
- if you experience new or sudden worsening of breathing difficulties, possibly accompanied by cough or fever. These could be symptoms of lung inflammation (interstitial lung disease), which may be life-threatening.
- if you experience severe stomach or intestinal pain, fever, chills, nausea, vomiting, or abdominal stiffness or swelling, as these could be symptoms of a tear in the wall of the stomach or intestines (“gastrointestinal perforation”). Also, inform your doctor if you have previously had gastrointestinal ulcers or diverticular disease, or if you are receiving concomitant treatment with anti-inflammatory drugs (NSAIDs) (used to relieve pain and swelling) or steroids (used for inflammation and allergies), as this may increase the risk.
- if you experience redness and severe eye pain or worsening of these symptoms, increased tearing, blurred vision, and/or sensitivity to light. You may need urgent treatment.
See also section 4 “Possible side effects”.
Children and adolescents
GIOTRIF is not recommended for use in children and adolescents. Do not administer this medicine to children or adolescents under 18 years of age.
Other medicines and GIOTRIF
Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines, including herbal medicines and over-the-counter medicines.
In particular, the following medicines, if taken before GIOTRIF, may increase GIOTRIF levels in the blood and therefore the risk of side effects. Therefore, these medicines should be taken as far apart as possible from GIOTRIF. This means preferably leaving an interval of 6 hours (for medicines taken twice daily) or 12 hours (for medicines taken once daily) between taking GIOTRIF:
- Ritonavir, ketoconazole (except in shampoo), itraconazole, erythromycin, nelfinavir, and saquinavir, used to treat various types of infections.
- Verapamil, quinidine, and amiodarone, used to treat heart conditions.
- Cyclosporine A and tacrolimus, medicines that affect the immune system.
The following medicines may reduce the effectiveness of GIOTRIF:
- Carbamazepine, phenytoin, and phenobarbital, used to treat seizures.
- St. John’s wort (Hypericum perforatum), a herbal medicine used to treat depression.
- Rifampicin, an antibiotic used to treat tuberculosis.
Ask your doctor if you are unsure about when to take these medicines.
GIOTRIF may increase blood levels of other medicines, including the following:
- Sulfasalazine, used to treat inflammation/infection.
- Rosuvastatin, used to lower cholesterol.
Inform your doctor before taking these medicines together with GIOTRIF.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
You must avoid becoming pregnant while taking this medicine. If you could become pregnant, you should use effective contraceptive methods during treatment and for at least 1 month after taking the last dose of this medicine. This is because there may be a risk of harm to the unborn baby.
If you become pregnant while taking this medicine, you must inform your doctor immediately. Your doctor will decide with you whether to continue treatment or not.
You should seek advice from your doctor if you plan to become pregnant after taking the last dose of this medicine, as your body may not have completely eliminated the medicine.
Breastfeeding
You must not breastfeed while taking this medicine, as a risk to the nursing infant cannot be ruled out.
Driving and using machines
If you experience treatment-related symptoms affecting your vision (e.g., eye redness and/or irritation, dry eyes, watery eyes, sensitivity to light) or your ability to concentrate and react, you are advised not to drive or operate machinery until the side effects have resolved (see section 4 Possible side effects).
GIOTRIF contains lactose
This medicine contains a sugar called lactose. If your doctor has informed you of an intolerance to certain sugars, consult with them before taking this medicine.
3. How to take GIOTRIF
Follow exactly the instructions for using this medicine as given by your doctor. If in doubt, consult your doctor or pharmacist again.
Dosage
The recommended dose is 40 mg once daily.
Your doctor may adjust (increase or decrease) your dose depending on how well you tolerate this medicine.
When to take GIOTRIF
- It is important that you take this medicine without food.
- Take this medicine at least 1 hour before eating, or
- If you have already eaten, wait at least 3 hours before taking this medicine.
- Take this medicine once daily at approximately the same time each day. This makes it easier to remember to take your medicine.
- Do not break, chew, or crush the tablet.
- Swallow the tablet whole with a glass of plain water.
GIOTRIF is to be taken by mouth. If you have difficulty swallowing the tablet, dissolve it in a glass of plain water. Do not use any other liquids. Place the tablet in the water without crushing it and stir occasionally for about 15 minutes until the tablet has dissolved into very fine particles. Drink the liquid immediately. To ensure that you have taken the entire dose, refill the glass with water and drink it as well.
If you are unable to swallow and have a gastric tube, your doctor may recommend administering the medicine through the tube.
If you take more GIOTRIF than you should
Contact your doctor or pharmacist immediately. You may experience more severe adverse effects, and your doctor may interrupt treatment and provide supportive care.
If you forget to take GIOTRIF
- If your next dose is more than 8 hours away, take the missed dose as soon as you remember.
- If your next dose is within 8 hours, skip the missed dose and take the next dose at your usual time. Then continue taking your tablets as before.
Do not take a double dose (two tablets at once instead of one) to make up for a missed dose.
If you stop taking GIOTRIF
Do not stop taking this medicine without first consulting your doctor. It is important to take this medicine every day as long as your doctor prescribes it. If you do not take this medicine as prescribed, your cancer may start to grow again.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, GIOTRIF may cause adverse effects, although not everybody experiences them.
Immediately inform your doctor if you notice any of the following serious adverse effects. In some cases, your doctor may need to interrupt treatment, reduce your dose, or stop treatment altogether:
- Diarrhoea (very common, may affect more than 1 in 10 patients).
Diarrhoea lasting more than 2 days or severe diarrhoea may lead to fluid loss (common, may affect up to 1 in 10 patients), low potassium levels in the blood (common), and worsening of kidney function (common). Diarrhoea can be treated. As soon as the first symptoms of diarrhoea appear, drink plenty of fluids. Inform your doctor immediately and start appropriate anti-diarrhoeal treatment as soon as possible. You should have an anti-diarrhoeal medicine available before starting treatment with GIOTRIF.
- Skin rash (very common).
It is important to start treatment of the rash as early as possible. Inform your doctor as soon as a rash appears. If treatment for the rash is ineffective and the rash worsens (for example, if your skin begins to peel or blisters appear), inform your doctor immediately, as your doctor may decide to discontinue treatment with GIOTRIF. The rash may appear or worsen in areas of skin exposed to sunlight. It is recommended to wear appropriate clothing and use sunscreen as protective measures against sunlight.
-
Inflammation of the lungs (uncommon, may affect up to 1 in 100 patients), known as "interstitial lung disease". Immediately inform your doctor if you notice new or rapidly worsening shortness of breath, possibly accompanied by cough or fever.
-
Eye irritation or inflammation
Eye irritation or inflammation may occur (conjunctivitis/dry eye occurs commonly and keratitis occurs uncommonly). Inform your doctor if you experience sudden onset or worsening of eye symptoms such as eye pain, redness, or dry eyes.
If you experience any of these symptoms, inform your doctor as soon as possible.
The following adverse effects have also been reported:
Very common adverse effects (may affect more than 1 in 10 patients):
- Mouth inflammation and mouth sores
- Nail infection
- Loss of appetite
- Nosebleed
- Nausea
- Vomiting
- Itching
- Dry skin
Common adverse effects (may affect up to 1 in 10 patients):
- Pain, redness, swelling, or peeling of the skin on hands and feet
- Increased levels of the liver enzymes aspartate aminotransferase and alanine aminotransferase in blood tests
- Inflammation of the inner lining of the bladder with a burning sensation when urinating and a frequent and urgent need to urinate (cystitis)
- Altered taste (dysgeusia)
- Stomach pain, indigestion, heartburn
- Inflamed lips
- Weight loss
- Runny nose
- Muscle spasms
- Fever
- Nail problems
Uncommon adverse effects (may affect up to 1 in 100 patients):
- Inflammation of the pancreas (pancreatitis)
- Development of a tear in the wall of your stomach or intestines (gastrointestinal perforation)
- Abnormal growth of eyelashes (including misdirected growth that may cause damage to the eye surface)
Rare adverse effects (may affect up to 1 in 1,000 patients):
- Formation of severe blisters or skin peeling (indicative of Stevens-Johnson syndrome and toxic epidermal necrolysis)
Reporting of adverse effects
If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of GIOTRIF
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton, the bag, and the blister after EXP. The expiry date refers to the last day of the month indicated.
Store in the original packaging to protect it from moisture and light.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.
6. Contents of the container and other information
Composition of GIOTRIF
- The active substance is afatinib. Each film-coated tablet contains 30 mg of afatinib (as dimaleate).
- The other components are monohydrate lactose, microcrystalline cellulose (E460), colloidal anhydrous silica (E551), crospovidone type A, magnesium stearate (E470b), hypromellose (E464), macrogol 400, titanium dioxide (E171), talc (E553b), polysorbate 80 (E433), indigo carmine aluminum lake (E132).
Appearance of the product and contents of the container
GIOTRIF 30 mg are dark blue, round, film-coated tablets. They are marked with the code “T30” on one side and the Boehringer Ingelheim logo on the other.
GIOTRIF film-coated tablets are available in packaging containing 1, 2, or 4 pre-scored unit-dose blisters. Each blister contains 7 x 1 film-coated tablets and is packed in an aluminum bag together with a desiccant sachet which must not be swallowed.
Only certain package sizes may be marketed.
Marketing Authorization Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Belgium/Belgium/Belgium Boehringer Ingelheim SComm Tel/Tel: +32 2 773 33 11 | Lithuania Boehringer Ingelheim RCV GmbH & Co KG Lithuanian Branch Tel: +370 5 2595942 |
| Luxembourg/Luxembourg Boehringer Ingelheim SComm Tel/Tel: +32 2 773 33 11 |
Czech Republic Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Hungary Boehringer Ingelheim RCV GmbH & Co KG Hungarian Branch Tel: +36 1 299 8900 |
Denmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88 | Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Germany Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 900 | Netherlands Boehringer Ingelheim B.V. Tel: +31 (0) 800 22 55 889 |
Estonia Boehringer Ingelheim RCV GmbH & Co KG Estonian Branch Tel: +372 612 8000 | Norway Boehringer Ingelheim Norway KS Tlf: +47 66 76 13 00 |
Greece Boehringer Ingelheim Hellas Monoprosopi A.E. Tel: +30 2 10 89 06 300 | Austria Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105‑7870 |
Spain Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Poland Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Croatia Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | Romania Boehringer Ingelheim RCV GmbH & Co KG Vienna - Bucharest Branch Tel: +40 21 302 2800 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenia Boehringer Ingelheim RCV GmbH & Co KG Ljubljana Branch Tel: +386 1 586 40 00 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Boehringer Ingelheim RCV GmbH & Co KG Organizational Unit Tel: +421 2 5810 1211 |
Italy Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Finland Boehringer Ingelheim Finland Ky Tel/Tel: +358 10 3102 800 |
Cyprus Boehringer Ingelheim Hellas Monoprosopi A.E. Tel: +30 2 10 89 06 300 | Sweden Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvia Boehringer Ingelheim RCV GmbH & Co KG Latvian Branch Tel: +371 67 240 011 | United Kingdom (Northern Ireland) Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Date of the most recent review of this leaflet:
Other sources of information
Detailed information on this medicinal product is available on the website of the European Medicines Agency: https://www.ema.europa.eu.
